By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



205 East 42nd Street, 16th Floor

New York  New York  33324  U.S.A.
Phone: 973-242-0005 Fax: n/a


Company News
Is This Fake News? Neurotrope (NTRP) Alzheimer's Release Takes Weird Spin 5/5/2017 6:16:48 AM
Neurotrope (NTRP) Craters As Alzheimer's Drug Fails To Impress In Mid-Stage Study 5/1/2017 6:26:41 AM
Neurotrope To Release Results From Phase II Clinical Trial In Moderate To Severe Alzheimer’s Disease On May 1, 2017 4/28/2017 9:04:37 AM
Neurotrope Announces Approval For Listing On The NASDAQ Capital Market 3/27/2017 8:36:34 AM
Neurotrope Concludes Patient Dosing And Monitoring In Its 148 Patient Phase II Clinical Trial Of Moderate To Severe Alzheimer's Dementia 2/28/2017 6:48:28 AM
Neurotrope Completes Licensing Agreement For Accelerated Synthesis Of Alzheimer's Drug Bryostatin-1 1/30/2017 6:46:03 AM
Neurotrope Release: Biotech Announces Reverse Split Of Common Stock In Preparation For NASDAQ Uplisting 1/12/2017 6:45:41 AM
Neurotrope Issues Statement On Eli Lilly (LLY)'s Solanezumab 11/23/2016 9:04:45 AM
Neurotrope Completes Enrollment In Its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial Of Bryostatin In Patients With Moderate To Severe Alzheimer's Disease 11/22/2016 7:54:20 AM
Neurotrope Announces Private Placement of $20 Million 11/18/2016 7:30:51 AM